Cargando…
Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993927/ https://www.ncbi.nlm.nih.gov/pubmed/33786453 http://dx.doi.org/10.1016/S2665-9913(21)00077-1 |
| _version_ | 1783669656645533696 |
|---|---|
| author | Dougados, Maxime |
| author_facet | Dougados, Maxime |
| author_sort | Dougados, Maxime |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7993927 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-79939272021-03-26 Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic Dougados, Maxime Lancet Rheumatol Comment Elsevier Ltd. 2021-06 2021-03-25 /pmc/articles/PMC7993927/ /pubmed/33786453 http://dx.doi.org/10.1016/S2665-9913(21)00077-1 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Comment Dougados, Maxime Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic |
| title | Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic |
| title_full | Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic |
| title_fullStr | Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic |
| title_full_unstemmed | Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic |
| title_short | Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic |
| title_sort | managing patients with rheumatic diseases treated with rituximab during the covid-19 pandemic |
| topic | Comment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993927/ https://www.ncbi.nlm.nih.gov/pubmed/33786453 http://dx.doi.org/10.1016/S2665-9913(21)00077-1 |
| work_keys_str_mv | AT dougadosmaxime managingpatientswithrheumaticdiseasestreatedwithrituximabduringthecovid19pandemic |